Literature DB >> 6613467

The effect of cimetidine on liver blood flow in anesthetized man.

G Tyden, L Thulin, B Nyberg.   

Abstract

In eight patients subjected to abdominal surgery, the effect of intravenous cimetidine (Tagamet) on hepatic arterial blood flow and portal blood flow was studied, utilizing electromagnetic blood flowmetry. Following cimetidine an increase in hepatic arterial blood flow concomitant with a decrease in mean arterial pressure were detected. Calculated hepatic artery vascular resistance was therefore significantly decreased by 28% after 2 min and 17% after 10 min. There was no change in portal blood flow. It is suggested that this effect of cimetidine is due to increased plasma histamine levels after acute H2 receptor blockade.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6613467

Source DB:  PubMed          Journal:  Acta Chir Scand        ISSN: 0001-5482


  8 in total

Review 1.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions.

Authors:  S R Smith; M J Kendall
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 4.  Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists.

Authors:  A A Fisher; D G Le Couteur
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

Review 5.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

6.  Effect of cimetidine on portal pressure and systemic hemodynamics in patients with and without liver cirrhosis.

Authors:  N Nagasue; Y Ogawa; H Yukaya; M Okita; M Yamamoto; T Higashi
Journal:  Gastroenterol Jpn       Date:  1985-04

Review 7.  Adverse reactions and interactions with H2-receptor antagonists.

Authors:  J Penston; K G Wormsley
Journal:  Med Toxicol       Date:  1986 May-Jun

8.  Pharmacological attempts to improve the bioavailability of oral etoposide.

Authors:  S P Joel; P I Clark; L Heap; L Webster; S Robbins; H Craft; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.